Isamu Okamoto

发表

Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.

Kazuko Sakai, Taroh Satoh, Kazuhiko Nakagawa, 2011, Biochemical and biophysical research communications.

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms

Bin Fang, Steven Eschrich, Giulio Superti-Furga, 2013, Molecular systems biology.

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer

Kazuko Sakai, Kazuhiko Nakagawa, Kaoru Tanaka, 2012, Clinical Cancer Research.

Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix‐assisted laser desorption ionization mass spectrometry imaging: a pilot study

Yasuhiro Fujiwara, Mitsuhiro Hayashi, Hiroaki Aikawa, 2018, British journal of pharmacology.

TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non–Small Cell Lung Cancer with an EGFR Mutation

Wataru Okamoto, Masahiro Fukuoka, Kazuhiko Nakagawa, 2010, Molecular Cancer Therapeutics.

Human Ect2 Is an Exchange Factor for Rho Gtpases, Phosphorylated in G2/M Phases, and Involved in Cytokinesis

T. Miki, I. Okamoto, T. Tatsumoto, 1999, The Journal of cell biology.

Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations

Koichi Yamazaki, Satoshi Morita, Masahiro Fukuoka, 2009, Clinical Cancer Research.

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

Koichi Goto, Masahiro Fukuoka, Makoto Nishio, 2014, The Lancet. Oncology.

Abstract 1731: TAK-701, a humanized monoclonal antibody to HGF, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with anEGFRmutation

Wataru Okamoto, Masahiro Fukuoka, Kazuhiko Nakagawa, 2011 .

Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase

Masahiro Fukuoka, Kenji Tamura, Junji Uchida, 2008, Molecular Cancer Therapeutics.

Elevated JNK activation contributes to the pathogenesis of human brain tumors

Mehdi Tnani, Andrew K Godwin, A. Godwin, 2002, Oncogene.